Testing a slow-release oral Parkinson's drug
Part of Brain & nervous system clinical trials.
This trial tests a new oral slow-release formula for Parkinson's disease, first in healthy people to check safety. If you are healthy and not on regular medications, you may be able to help evaluate this new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult between 18 and 65 years old.
- You should not have any medical conditions that require taking daily medications.
- You need to be willing and able to complete all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single dose of a new tablet medication (called TRTL-729) in healthy adults. It helps researchers learn how the drug is absorbed and tolerated, which is a first step in developing a treatment.
This trial tests an experimental oral drug (called ABBV-1162) in healthy adults to see how the body handles it and to check for any side effects. It is one of the first steps in testing a new medicine.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
Hear when a new Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.